Last Updated on January 6, 2024 by The Health Master
Aurobindo Pharma said it has received Voluntary Action Indicated (VAI) from the US health regulator for its Telangana-based manufacturing plant.
As per the information available on the United States Food and Drug Administration (USFDA) website, the company’s Unit – IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated (VAI), the drugmaker said in a regulatory filing.
The USFDA inspected the site from November 10 to November 18, 2022.
As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action.
NPPA asks Pharma Companies to register in IPDMS 2.0
CDSCO panel gives nod for Icosapent Ethyl Capsules
NPPA decided to address the issue of inter brand price variation
FDA Haryana: Medical store sealed, drugs being sold at prices higher than MRP
Pharma employee held by Mumbai police in spurious injection case
Dissolution test: Importance in Pharma Industry
Updated list of Medical Device Testing Laboratories (MDTLs)
Lux level in Industry (Pharma, Cosmetics, Homeopathy & Medical Devices)
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
